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OBJECTIVES: Evaluating different doses of caffeine (CAF) on heart rate (HR) variability 
(HRV) during and following exercise in order to assess its impact on autonomic control. We 
intended to evaluate the influence of CAF as a supplement before exercise on HRV through a 
systematic review. DATA SOURCES: Manuscripts were selected based on electronic searches 
of MEDLINE, EMBASE and CINAHL databases from 2010 to 2019 and followed the protocol 
Preferred Reporting Items for Systematic Reviews and Meta-Analyzes (PRISMA). 
ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Blind randomized designs and 
controlled trials that reported the influence of CAF on HRV during exercise and during recovery 
from exercise, with strength of evidence assessed using the GRADE system; the search for the 
studies was organized using the PICOS strategy. RESULTS: A total of 1797 articles were 
recognized, following the screening and eligibility stages, 9 studies continued to the final 
sample. Six studies reported that the combination of CAF supplementation with physical 
exercise exhibited higher HR when compared to the placebo group during post-exercise 
recovery; additionally, prolonged activation of sympathetic cardiac control and delayed 
parasympathetic reactivation following exercise was observed. However, three studies 
demonstrated no CAF influence when using similar doses. SUMMARY/CONCLUSION: 
This review observed equivocal results in HR and HRV recovery following exercise with the 
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presence of CAF consumption. These findings cannot confirm the cardiac autonomic changes 
observed where entirely due to the influence of CAF, and further studies should be performed 
to better understand this relationship. 






Caffeine (CAF) is one of the most widely utilized supplements in sports1, and can be 
consumed in a variety of forms (e.g., energy drinks, coffee, etc.). The isolated form of CAF is 
classified as a methylxanthine, which can be quickly absorbed through the gastrointestinal tract 
and freely pass through the blood brain barrier2. In as early as 15-45 minutes, elevated systemic 
levels of CAF are observed with peak concentrations occurring within the hour. According to 
the international society of sports nutrition position stand on CAF, consumption enhances 
aerobic performance, high-intensity exercise performance, and mental vigilance2. It is this 
relationship to CAF consumption that has led its wide acceptance amongst consumers as a 
strategy to improve their physical performance3-11. 
Recommended doses of CAF are widely variable12, but can be best classified into three 
groups; low (up to 3mg/kg), moderate (between 5 and 6mg/kg) and high (9mg/kg) dosage13. 
The Food Drugs and Administration (FDA) states that CAF intake up to 400 mg/day (~5mg/kg) 
is not associated with adverse health effects14; however, excessive doses of CAF consumption 
have shown acute symptoms such as anxiety, headaches and restlessness15,16, as well as 
increased risk of hypertension and cardiovascular disease.16,17 Furthermore, dosages of 9mg/kg 
and 13mg/kg did not cause significant differences in exercise performance when compared to 
5mg/kg dosage18, suggesting higher doses of CAF are unnecessary. 
The manner in which CAF influences cardiovascular function is through the obstruction of 
adenosine receptors (A1 and A2) and activation of the sympathetic autonomic nervous system 
through the increased release of catecholamines in blood plasma19. These functions then result 
in tachycardia9 and increased time to muscular fatigue10. Though seemingly innocuous, these 
alterations were believed to be related to elevated risks of arrhythmias20. A study by Magkos et 
al.21 emphasized that the physiological changes triggered by the combination of CAF and 
exercise may be unfavorable without familiarity of cardiovascular parameters and the 
individuals’ characteristics. These findings suggest that depending on physical activity 
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intensity, CAF may become a contributing factor for harmful cardiovascular complications 
following exercise22. However, the majority of literature is in near agreement that moderate 
doses of CAF do not increase risk of untoward cardiac events23,24. Furthermore, an earlier study 
assessed patients with high risk for ventricular arrhythmias and heart failure who acutely 
consumed 500 mg (~6mg/kg) of CAF and completed a treadmill test. As a main outcome, the 
authors reported that CAF increased peak systolic and diastolic blood pressure during exercise, 
but was unable to induce arrhythmias. In agreement to this, several studies have found that 
alterations as the result of moderate CAF ingestion are trivial and do not appear to enhance risk 
to arrhythmia23,24. 
The vast majority of studies that have examined CAF and cardiovascular function 
evaluated heart rate (HR) and electrocardiograms (ECG) for presence of arrhythmias. To this 
point, a key aspect of cardiovascular function through control of the autonomic nervous system 
(ANS) may have been overlooked. The ANS plays a key role in controlling blood pressure and 
HR25 and can be measured through HR variability (HRV), which is a non-invasive technique 
that assesses autonomic regulation of heart rhythm26. HRV is one of the most practical 
approaches to analyze the ANS function, both under pathological and normal physiological 
conditions26. This method assesses the inter beat intervals (RR-intervals) oscillations, providing 
information about the parasympathetic and sympathetic influence on the sinus node27. 
Importantly, HRV provides a different metric by which cardiovascular function may be 
enhanced or inhibited, independent of changes in HR or the presence of arrhythmias27. 
In this manner, we posed the following question: What is the influence of a CAF 
supplement before exercise on HR autonomic control? Evidence concerning the effects of CAF 
on HRV may contribute to the planning of novel strategies regarding the CAF consumption in 
order to prevent cardiovascular complications after exercise. Thus, we aimed to evaluate the 





This review was described through a systematized search, during the months of January at 
August 2019, founded on articles published and available in of MEDLINE, EMBASE and 
CINAHL. The review was achieved according to the protocol Preferred Reporting Items for 
Systematic Reviews and Meta-Analyzes (PRISMA)28 and the protocol for this review was 
published on PROSPERO (Protocol registration number PROSPERO CRD42019126347). 
Search strategy 
 
The identification of the articles was completed via the keywords obtained by the Medical 
Subject Headings (MeSH), which is the National Library of Medicine controlled vocabulary 
thesaurus used for indexing articles for PubMed. The research and selection of the studies were 
organized using the Population Intervention Comparison Outcome Study Design (PICOS) 
strategy. In this model, the search strategy was defined according to Population (P), Intervention 
(I), Control (C), Outcomes (O) and Study Design (S), with Mesh allocated in each category 
according to its search characteristic, with the purpose of optimizing the search: P – Healthy 
subjects, I – Caffeine and Exercise, C – Placebo and Exercise, O - Heart rate variability and 
heart rate, S – Randomized trials, single and double blind, crossover and controlled designs. 
The following search terms were applied: “Autonomic Nervous System” OR “Heart Rate 
Variability” OR “Sympathetic Nervous System” OR “Parasympathetic Nervous System” OR 
“Autonomic Dysfunction” OR “Vagal Nerve” AND “Caffeine” AND “Exercise” in the titles 
and/or in the abstracts. After identifying the studies, the references were initially screened by 
applying the search criteria in the databases, using the following filters: studies undertaken in 
the past 10 years (2010 to 2019), free complete texts and use of English language. 
The translocation of the identified studies in the databases for a matrix spreadsheet was 
commenced, where they were organized by numbering, database, author and year, title, journal, 
sample, main findings, conclusion and reason for exclusion; and this process signifies the 
beginning of the eligibility stage. In this procedure, the studies were subject to exclusion if they 
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were unable to make an actual reference to the proposed revision theme, being evaluated by the 
title and abstract. Next, studies that did not have the relevant credentials to be excepted were 
read in their entirety. An inclusion criteria considered specific references to the proposed theme 
of the review and demonstration in methods section a technique to measure HRV, including 
electrocardiogram (ECG) or HR monitors with appropriate scientific validation (Polar®, 
Kempele, Finland; Models: V80029, RS80030, S810i31). 
The final stage of selection for inclusion of the articles was performed by reading the 
complete articles, which was undertaken by two independent researchers. If there was a 
disagreement about the inclusion of a particular article, another additional reviewer was 
consulted for a final decision (once). Studies concluded this entire review process and, if the 
researchers decision was to be included, were assigned to a table with the subsequent 
information extracted: Author and Year. Sample, HRV Indices, Dosage and Main Conclusion, 
due to the order they were found in the databases. 
Data analysis 
 
The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) 
Working Group (GRADE Working Group, 2004)32 was followed in order to analysis the 
strength of evidence, including study design, broadly categorized as observational studies (low 
evidence) and randomized trials (high evidence). Study quality (detailed study methods and 
execution) and significant limitations secondarily were considered in strength of evidence 
analysis. 
Study eligibility criteria 
Patients (subjects) 
We included studies with healthy physically active human adults (between 18 to 50 years 
old) and athletes. We excluded studies that enrolled individuals with cardiorespiratory, 
neurological, musculoskeletal, renal, metabolic, endocrine and other reported impairments that 
circumvented the acceptable performance of the physical exercise procedures. We standardized 
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this inclusion and exclusion criteria in order to evaluate the CAF impact in trained subjects that 
use this compound for training and to facilitate physiological interpretation. 
Intervention 
 
The references nominated were based on CAF taken combined with exercise. CAF dose 
ranged between 100-500 mg and between 2-5mg/kg, following recommendation from the FDA 
(up to 400 mg). We included studies that prescribed CAF in combination with another 
supplement (Citrus aurantium - ~1mg/kg – and Taurine – 25mg/kg). Studies that used CAF 
combined with carbohydrates were excluded. No criteria were established for the form of 
physical exercise or sports modality in which the intervention with the CAF was proposed. 
Control 
 
We included references with the following placebo as controls: 1) dextrose capsule; 2) 
opaque gelatin capsule; 3) bottled mineral water with artificial refreshment; 4) starch capsule; 








The principal outcome assessed was the linear indices of HRV: RMSSD (square root of 
the mean square of the differences between adjacent normal RR intervals), SDNN (standard 
deviation of all normal RR intervals), pNN50 (percentage of adjacent RR intervals with 
duration difference greater than 50 milliseconds), HF (high frequency), LF (low frequency), 
LF/HF ratio (Relation between low and high frequency components), SD1 (dispersion of points 
perpendicular to the identity line, instantaneous record of beat-to-beat variability), SD2 (scatter 
points along the identity line, long-term record). Secondary outcomes involved HR, HRmax 
(HR peak during exercise), DBP (diastolic blood pressure) and SBP (systolic blood pressure). 
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This outcome was selected because they provide consistent information regarding 
cardiovascular and autonomic recovery following exercise. 
Study Design 
 




Descriptive statistical analysis of the references are presented in mean + standard 
 






The identification of the studies through search in the databases, MEDLINE, EMBASE 
and CINAHL resulted in 1797 articles referring to the appropriate cited terms. After sifting the 
articles through the screening steps, 161 articles were eligible to be read. After the eligibility 
stage only nine studies progressed to the final sample for this review. The search process and 
selection phases are illustrated in the Flow Diagram following the PRISMA protocol (Figure 
1). 
Description of the characteristics of the study population are presented in Table 1, while 
description of the selected articles by author and year, time ingestion CAF, CAF dose, placebo, 
analysis time, HRV index, main conclusions, strength of evidence and effect size through 
Cohen’s d is shown in Table 2. 
Nelson et al.33 developed a study evaluating the effects of CAF in combination with 
physical exercise on HRV parameters in young adults (25.5 ± 4.1 years old and body mass 
index (BMI) of 25.1 ± 4 kg/m2). In their study, CAF (2mg/kg) was presented via an energy 
drink containing Taurine (25mg/kg). The administration of about 198.2 ± 1.4 mg of CAF 
increased HRmax during the exercise (CAF: 145.4 ± 4.8 vs Placebo: 133.1 ± 4.9, Cohens’d= 
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2.53, a large effect size). The authors detected that 60 minutes after exercise cessation, the CAF 
group maintained the highest HR levels (CAF: 82.8 ± 1.9 vs Placebo: 77.9 ± 3.8, 
Cohens’d=1.43, a large effect size). Although the participants who ingested the beverage 
exhibited an increase in resting HR, the HRV analysis revealed no changes when compared to 
the placebo group. In addition to the previously mentioned study, Kliszczewicz et al.34 proposed 
to evaluate the effects of 100 mg of CAF in combination with 100 mg of Citrus Aurantium 
(~1mg/kg). The evaluation was completed prior to physical exercise and displayed an increase 
in HR and sympathetic activity despite no observed changes in resting parasympathetic activity. 
Yet, cardiac autonomic modulation was unaffected during the recovery period after physical 
exercise. Conversely, the studies that prescribed CAF alone established consistent outcomes 
regarding the influence of CAF on autonomic cardiac modulation and cardiovascular 
parameters which is the main outcome of this review. 
Bunsawat et al.35 prescribed 400 mg (5mg/kg) of CAF in 18 healthy subjects (26 ± 1 years 
 
of age and BMI: 23.9 ± 0.8 kg/m2). In the CAF group there was a delay of cardiac autonomic 
recovery in the post-exercise period (LF/HF), also, it maintained high BP, DBP and SBP values 
after the exercise termination. Gonzaga et al.36 supported their results and reported that CAF 
delayed RMSSD and SD1 recovery after exercise in physically active men., The ingestion of 
300 mg (~4mg/kg) of CAF in 32 physically active men (23.59 ± 3.45 years old and BMI: 24.40 
± 2.82 kg/m2) delayed vagal recovery after submaximal aerobic exercise (RMSSD and SD1), 
and promoted the persistence of elevated levels of blood pressure36. 
In addition, Gonzaga et al.37 also assessed the effects of 300 mg (~4mg/kg) CAF on HR 
autonomic recovery in two groups of healthy young men according to aerobic capacity (low 
VO2: <42.46 ml / kg / min vs. high (VO2: > 42.46 ml / kg / min). The low aerobic capacity 
group showed a delay in parasympathetic recovery after performing 30 minutes of submaximal 
aerobic exercise (60% VO2 max). On treadmill test, these effects were observed taking into 
account the RMSSD, SD1 and SD2 indexes. 
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Studies that achieved an adequate measurement of the HRV analysis during the recovery 
period and prescribed CAF alone exhibited promising outcomes in relation to recovery status 
of the cardiac autonomic activity. The two aforementioned studies evaluated the HRV indices 
for 30 minutes in the recovery period, which gives more credibility and reliability to the results. 
Alternatively, Lopes-Silva et al.38 evaluated 10 male Taekwondo athletes (21 ± 4 years old, 
eutrophic and 9 years of experience) and Rolim et al.39 evaluated 21 physically active men (22.3 
± 2.9 years old and BMI: 25.2 ± 2.7 kg/m2) and discovered different outcomes when taking 
CAF at concentrations of 5mg/kg (355 ± 64.5mg) and 3mg/kg, respectively. In the Lopes-Silva 
et al.37 study, the CAF was unable to provoke a delay in vagal reactivation and, for the Rolim 
et al.38 study, the parasympathetic regulation was revealed to be high compared to the placebo 
group. However, they performed an ultra-short-term recovery analysis, which persisted for 300 
and 360 seconds, respectively, which probably led the two studies to achieve different results 
to those reported in the research literature. 
The other four studies included in the review did not perform HRV analysis. Only the HR 
was evaluated. The study conducted by Smirmaul et al.40 comprised of seven physically active 
men (29 ± 6 years old and eutrophic) who ingested 4mg/kg (300 ± 32mg) of CAF prior to 
training in high intensity cycling. The HRmax of the CAF group presented statistically higher 
values (CAF: 185 ± 6 bpm vs. Placebo: 179 ± 7bpm, p = 0.006). We computed an effect size, 
which provided Cohen’s d=0.92; which is a large effect size. Glaister et al.41 involved 16 male 
triathletes (38 ± 8 years old) accustomed to consuming a daily average of 225 ± 135mg of CAF 
and who covered an average distance of 221 ± 65km per week. After the ingestion of 5mg/kg 
(383 ± 39mg) of CAF, the participants were evaluated prior to exercise and after performing 
physical exercise on an ergometric bicycle. The CAF reduced the resting HR (CAF: 59.5 ± 8.1 
bpm vs Placebo 63.0 ± 7.8 bpm, Cohen’s d=0.44, a small effect size) and did not influence HR 
30 minutes after physical exercise (CAF: 70.8 bpm ± 9 vs. 72.2 ± 10.5 bpm, Cohen’s d=0.14, 







This review set out to investigate the consequences of CAF on HR and HRV following 
exercise. Among the nine studies evaluated, six reported that deviations in HRV are dependent 
on the combination of three main factors: CAF dosage, type of exercise, and cardiorespiratory 
fitness. In regards to HR induced changes by CAF in exercise, we observed the following: 1) 
increased HR during exercise and throughout the recovery period; 2) prolonged post exercise 
sympathetic activity; 3) and delayed vagal reactivation. These effects can be greatly attributed 
to an increase in catecholamine release into the bloodstream prompted by CAF42. Nonetheless, 
three references did not support this assumption.34,35,37 In order to provide specific details 
concerning the influence of CAF on recovery from exercise, we divided Discussion section in 
topics related to HR, HRV indices and CAF dosage. 
CAF and HR 
 
The most extensively measured variable evaluated in this review was HR. It was observed 
that the majority of studies indicated that CAF has the capacity to influence HR before, during, 
and following exercise33-41, though responses appeared to vary. The least represented period 
measured for HR was during the resting phase (i.e., ingestion period). Of the studies that were 
evaluated, all reported values for resting HR. Of them, only four reported HR following the 
consumption of CAF or CAF supplement33,34,36,41. Glaister et al.41 found a decrease in HR in 
the group that took 5mg / kg of CAF (CAF: 59.5 ± 8.1 bpm vs. Placebo: 63 ± 7.8 bpm). The 
study performed by Gonzaga et al.35 found no significant differences in HR between CAF 
supplementation or placebo protocols. Conversely, Nelson et al.33, found that there was an 
increase in resting HR in the group that ingested CAF compared to placebo following its 
ingestion, though the exact change was not reported. Lastly, when evaluating a CAF complex, 
Kliszczewicz et al.34 found that resting HR increased 45-minutes following its consumption 
(59.7 ± 7.93 to 64.6 ± 9.13 bpm). It is important to note that the studies selected for this review 
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included an exercise bout or trial, which may have elicited an emotional response that resulted 
in an elevated resting HR. Future studies should implement emotional based scales to better 
understand this relationship. 
During periods of exercise CAF appears to have equivocal effects on HR. Smirmaul et al.40 
 
reported that the effect of CAF was able to increase HR during cycling exercise in both the 
isotime and time to exhaustion trials when compared to placebo. The authors suggested that 
differences in peak HR were not related to exercise performance, but rather the effect of the 
CAF supplement. Bunsawat et al.35 showed a modest, yet significant difference in the observed 
HRmax (189 ± 2 bpm vs 192 ±2 bpm) in the CAF group during a maximal treadmill bout. 
Lopes-Silva et al.38 observed higher mean HR during three rounds of a Taekwondo protocol: 
Round  1) CAF:  170 ±  8 bpm  vs. Placebo:167 ±  13 bpm;  Round 2) CAF:  175 ± 6 bpm  vs. 
Placebo: 173 ± 10 bpm; Round 3) CAF: 178 ± 6 bpm vs. Placebo: 177 ± 10 bpm, but were not 
enough to be significantly different. In contrast to the aforementioned increases in peak HR, 
Glaister et al.41 found that at rest and during the early stages of an incremental cycle test, the 
CAF trial demonstrated lower HR; however, this relationship was lost at higher levels of 
exercise intensity. Supporting this was Gonzaga et al.36, Nelson et al.33 and Kliszczewicz et al.34 
whom found no differences in peak HRs between CAF and Placebos. In the studies that failed 
to demonstrate peak differences, two performed exercise bouts that where considered sub- 
maximal, which may have failed to elicit enough of a cardiovascular stress to elicit differences 
in peak HR. Conversely, the other two studies were considered to be maximal effort exercises 
and therefore may have induced maximal obtainable peaks in both trials. In all, it would appear 
that the supplementation of CAF results in an increased HR during high-intensity exercise bouts 
that are shy of maximal intensity. 
Five of the reviewed studies examined HR during the recovery periods following exercise. 
Bunsawat et al.35 and Lopes-Silva et al.38 observed similar delays in heart return during early 
phases of recovery when compared to placebo controls. However, Gonzaga et al.36, Glaister et 
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al.41 and Kliszczewicz et al.34 found no differences between CAF and placebo protocols 
regarding HR during recovery from exercise. Some of the differences observed may be due to 
the exercise intensity, which the protocols of Bunsawat et al.35, Lopes-Silva et al.38 and 
Kliszczewicz et al.34 were all considered to be of high-intensity. Interestingly, Kliszczewicz et 
al.34 was the only one to demonstrate no changes in post exercise HR, which may be due to the 
dosage of CAF used in the protocol, which was 2-4 times less than that used in the Bunsawat 
et al.35 and Lopes-Silva et al.38 studies. Though there is limited information, it would appear 
that higher dosages of CAF in conjunction to higher intensity exercise may cause a delayed 
rebound in HR. 
CAF and HRV 
 
The prolonged delay of autonomic recovery following exercise is associated with higher 
cardiovascular risk43, and therefore the focus of many applied and clinical intervention 
studies44. A pragmatic technique to assess the efficiency of a given intervention is the evaluation 
of HRV pre-exercise and subsequent rebound post-exercise45. Though HRV and exercise alone 
have been widely evaluated, relatively little information regarding CAF supplementation on 
resting and recovering HRV status exists. Amongst the nine studies presented in this review, 
seven examined indices of HRV, with five examining resting33-38, and six examining recovery34- 
36, 37-39. The findings of these studies are equivocal and therefore inconclusive, further points of 
consideration are provided below. 
Similar to the HR markers evaluated in this review, resting HRV was the least represented. 
Though six of the papers measured resting values, Bunsawat et al.35 only reported HRV prior 
to supplement consumption, and therefore did not provide insight into the influence of CAF 
over resting values. Rolim et al.39, Gonzaga et al.36, Kliszczewicz et al.34 and Gonzaga et al.37 
all found no changes in resting markers of parasympathetic activity following the consumption 
of CAF or CAF complex. These findings are in accordance to several studies that have 
evaluated the ingestion of CAF at rest. However, it was noted that sympathetic activity was 
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increased in Kliszczewicz et al.34 with plasma catecholamines and LF being elevated 
independent of a static vagal activity. In contrast, Nelson et al.33 observed a vagal withdrawal 
one hour following the consumption of CAF when compared to the PLA group; however, direct 
changes from pre consumption to post consumption was not measured. The findings of this 
review suggest that there is little to no influence of CAF on markers of HRV. It is important to 
note that the majority of the studies compare post values to establish a difference between the 
supplement and PLA and therefore change relative to the condition may be lost. Future research 
should include pre and post consumption values to better assess the influence of CAF on HRV, 
especially in protocols involving exercise. 
A primary purpose of this review was to evaluate the influence of CAF on the rebound of 
HRV following exercise, overall the findings yielded conflicting results. Rolim et al.39 found 
that CAF triggered an accelerated vagal reactivation following a sub-maximal treadmill bout. 
This enhanced recovery should perhaps stand alone in the findings because they compared the 
HRV indices (SD1 and SD2) for only the first 3 minutes, whereas more commonly used indices 
(RMSSD, HF and LF) discard the first five minutes of the recording prior to analysis. The 
findings of Kliszczewicz et al.34 indicated that CAF did not influence cardiac autonomic 
recovery following a repeated Wingate protocol when compared to placebo. Similarly, Nelson 
et al.33 revealed that CAF in combination with taurine did not significantly change the linear 
time domain and frequency HRV indices when compared to placebo protocol. Bunsawat et al.35 
undertook a more comprehensive analysis during the 30-minute recovery period following a 
maximal exercise protocol; and evaluated several cardiac autonomic markers (HR, BP and 
HRV). It was reported that in the CAF trial delayed adjustments in the autonomic recovery via 
HR and BP; however, in regards to HRV only LF/HF indexes demonstrated this inhibited 
recovery. In agreement with the inferences made by Bunsawat et al.35, Gonzaga et al.36 and 
Gonzaga et al.37 reported that CAF delayed RMSSD during early stages of recovery following 
aerobic moderate exercise in healthy physical active men. 
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An additional consideration to these findings is cardiorespiratory fitness, which as a 
variable may relate to the influence of CAF on parasympathetic recovery after exercise. 
Gonzaga et al.37 identified a delay in the recovery of the RMSSD, SD1 and SD2 indices in the 
low aerobic capacity group (VO2 34.69 ± 6.92 mL / kg / min). These indices were evaluated 
over one hour after exercise and showed significant differences in recovery time compared to 
the high aerobic capacity group (VO2 53.32 ± 8.79 mL / kg / min). Though this presents an 
appealing covariant to the relation of CAF and vagal rebound, further evidence is needed to 
establish this relationship. 
The abovementioned references33-36 examined HRV, at minimum, during the initial 30 
minutes of recovery following exercise. We highlight that longer lasting analysis throughout 
the recovery period provides a more detailed identification of adjustments in cardiac activity43. 
Therefore, the assessment of recovery for a period greater than 30 minutes following exercise 
would be more reliable for interpretation of relevant outcome measures. Due to the inconsistent 
findings of this review no viable inferences can be made in regards to the influence of CAF on 
recovery. However, what can be determined is the need for further research to provide much 
needed insight into the conditions that may or may not influence the recovery of HRV. 
CAF Dosage 
 
CAF influences the cardiovascular system by acting as an inhibitor of monoamine oxidase, 
which induces increased levels of epinephrine, norepinephrine, serotonin and dopamine44. Due 
to this function, CAF should be capable of evoking tachycardic and pressor responses related 
higher sympathetic activity via beta adrenergic receptor activation in the heart sinoatrial node 
and alpha-1 adrenergic receptors in the systemic vasculature36-37. Moreover, CAF is also a 
ryanodine receptors agonist, which acts upon the sarcoplasmic reticulum, helping a Ca2+- 
specific channel45, thereby increasing contractility46. The magnitude of these effects appears to 
be influenced by dose. Studies have shown that small doses of CAF cause significant changes 
in the modulation of cardiac activity34. However, the effects of CAF appear to be nonlinear with 
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increasing dosage, demonstrating diminishing returns at higher levels 41. Within the included 
references of this review, different protocols and dosages of CAF supplementation were used 
(e.g., fixed values or relative to body weight). The dosages of CAF used were as follows: 100 
mg (~1mg/kg)34, 300 mg (~4mg/kg)36,39, 400 mg (~5mg/kg)35, 2mg/kg33, 3mg/kg39, 4mg/kg40, 
5mg/kg38,41. 
Kliszczewicz et al.34, evaluated subjects that participated in an exhaustive exercise 
protocol, which comprised of a one-minute warm-up period performed at 50 W with a rolling 
start into the Wingate test, with a 30-s duration. The volunteers were encouraged to pedal at 
their maximal effort against a resistance of 0.80 Nm/kg. The authors noted that ~1mg/kg CAF 
combined with the Citrus Aurantium (~1mg/kg) increased sympathetic control without 
influencing the parasympathetic recovery following effort. Supporting their findings, Gonzaga 
et al.36 evaluated a dosage of 300 mg (~4mg/kg) of CAF before moderate aerobic exercise and 
observed diminished post-exercise ANS recovery. A slower return of RMSSD and SD1 indices 
were also detected. 
Gonzaga et al.37 also demonstrated that the combination of CAF 300 mg (~4mg/kg) and 
submaximal aerobic exercise in people with low cardiorespiratory capacity resulted in delayed 
post-exercise vagal recovery. The RMSSD, SD1 and SD2 recovery showed significant 
differences compared to the high cardiorespiratory capacity group. In this case, the authors 
suggest sedentary subjects who take CAF before exercise should adhere to the dosage proposed 
by the FDA, in order to reduce the possibility of cardiovascular complications. 
In Lopes-Silva et al.38, the group that consumed CAF (5mg/kg, ~ 300 mg to 400 mg) 
consistently presented a higher HR when compared to control, but no changes in RMSSD was 
reported. However, this result may be related to the training experience of the participants 
(minimum 9 years). No statistical differences were observed between groups during the first 
150 seconds of recovery after the last session; however, the CAF group demonstrated a 
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constant, yet non-significant of heightened HR between 180 and 360 seconds after exercise 
cessation. 
Nelson et al.33 evaluated the supplementation of CAF 2mg/kg (around 120 and 160 mg) in 
 
combination with Taurine 25mg/kg prior to an aerobic exercise protocol. The only variable to 
demonstrate significant changes was HR, while no significant variation was observed in indices 
of HRV when compared to the placebo group. Energy drinks are difficult to evaluate in regards 
to the influence of CAF on exercise performance and physiological responses due to several 
ingredients and dosages. 
In summary, the studies that reported significant influence of CAF on cardiovascular 
variables or HRV used ~1mg/kg34, 2mg/kg33, ~4mg/kg36, 37, 4mg/kg40, and ~5mg/kg35 dosages, 
while no CAF effects were noted with 3mg/kg39 and doses of 5mg/kg38,41. In this scenario, we 
observe that there are equivocal results using similar doses. These findings raise the question: 
What is the most effective and safe dose of CAF is for exercise and cardiovascular health? The 
studies evaluated in this review do not totally support that CAF delays HRV recovery from 
exercise, though they did demonstrate alterations in autonomic control. Therefore, we suggest 
relative caution for people who plan to begin a physical exercise training and the use higher 
doses CAF. A medical consult and detailed physical examination is recommended before 
exercise initiation. 
CAF combined with supplements 
 
Two studies evaluated the effects of CAF combined with other supplements. 
Kliszczewicz et al.34, analyzed CAF combined with the Citrus Aurantium, they evidenced that 
this combination increased resting sympathetic control of heart rhythm but did not influence 
the parasympathetic HR recovery following exercise. Citrus Aurantium is extracted from the 
orange and contains the active ingredient of p-synephrine, a sympathomimetic protoalkaloid. It 
has been indicated as a mild central nervous system stimulant47; however, p-synephrine acts on 
beta-3 receptors on adipose tissue and do not exhibit any action on the heart. In this line, we 
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hypothesize that p-synephrine has a minimal effect of CAF. However, there is no previous study 
that evaluate the impact of Citrus Aurantium on cardiovascular and autonomic nervous systems 
during recovery from exercise. 
Nelson et al.33 investigated CAF in combination with Taurine before exercise. There was 
 
no significant change in HRV compared to placebo. The authors theorized that Taurine would 
attenuate the CAF stimulus on ANS. This proposition is supported by Rakmanee et al. 48, which 
evaluated the effects of taurine on autonomic nervous system in adult male rats. As a main 
finding, they reported that taurine supplementation decreased sympathetic renal nerve activity 
in animals with high sugar diet. Yet, there is a lack of conclusive evidence and more controlled 
studies needed to achieve an improved outcome. 
Taken together, the studies supported that taurine may attenuate the sympathetic activation 
and parasympathetic withdrawal caused by CAF, whereas Citrus Aurantium combined with 
CAF has no significant influence on HRV recovery. 
Points to be addressed 
 
Some points of consideration are worth highlighting regarding the studies selected for this 
review. Only one study used CAF as an energy drink (CAF combined with taurine )33, which 
demonstrated increased resting HR and no influence over HRV following exercise. The others 
investigated CAF in the form of capsules and pills. We believe that the mechanism of CAF 
supplementation may influence HRV recovery following exercise, since vagal activation 
induced by stomach volume changes may affect parasympathetic activity. These vehicles for 
supplementation should be further evaluated. 
Alternative types of physical exercise were applied in combination with CAF, the 
modalities or equipment necessary to accomplish the tests were: Treadmill35,36,37,39; Ergometric 
Bicycle33,34,40,41 and Fight38. Additionally, markers of ANS activity evaluated in this literature 
review differed in collection technique, timing, and indices, thus providing some variation in 
the interpretations. The references selected exposed differences between participants and, we 
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hypothesize that the greater the experience with physical activity, the better adaptation of the 
ANS to CAF. 
Taken together, we cite attention for more consideration to the effects of CAF ingestion 
before physical exercise and the possible deleterious effects on cardiovascular health of this 
grouping. Furthermore, we recommend more comprehensive evaluation of ANS activity during 
CAF supplementation through the ingestion and recovery periods. We recommend the 





Among the nine references evaluated, six evidenced that CAF delays cardiovascular and 
autonomic recovery following aerobic exercise, whereas three showed opposite results even 
with similar dosage. This review proposes that the effects of CAF in delaying HR and HRV on 
post-aerobic exercise recovery is still not totally supported by the current literature. Even 
though, we stress the importance of clinical and specific evaluation of individuals who intend 
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Figure 1. Flowchart of search strategy and selection of studies. Preferred Reporting Items for 




Table 1. Description of the characteristics of the study population of articles by author and year, sample, age (years), weight (kg), height (cm), 
BMI (kg/m²) (mean ± SD), exercise, average peak oxygen (ml/kg/min), exercise intensity. 
Author/years Sample Age (years) 
  
 












14 healthy men 25.1 ± 3.9 78.71 ± 9.53 177.2 ± 4.6 - Ergometric 
Bicycle 
- 50 and 100 rpm  at a 
resistance of 1.5 kp 
Smirmaul et 
al.33 
7 healthy and 
active men 
29 ± 6,0 75 ± 8,0 179 ± 8,0 - Ergometric 
Bicycle 
- 5 minutes Breathing hypoxic 
air, a heating cycle of 3 min 
to 40% PPO, a fixed period 
of 6 min (isotime) of cycling 
exercise in hypoxia at 78 ± 




32 healthy and 
active men 






26 ± 1,0 - - 23.9 ± 0,8 Treadmill - Maximum oxygen 
consumption (VO2max), 
followed by 2 minutes active 
recovery at a speed of 
3.5kmh and grade of 0%.24 




23.69 ± 3.75 78.38 ± 6.92 180 ± 4.0 24.33 ± 2.04 Treadmill Group: High VO2: 
53.32 ± 8.79 
 Low VO2: 34.69 
± 6.92 
 
60% on VO2peak during 
30minutes 
Glaister et al.34 
 
16 men cyclists 
and triathletes 
38 ± 8,0 76.6 ± 7,0 180 ± 5,0 - Cycle 
Ergometric 





10 men athletes 
and experienced 
in taekwondo 
21 ± 4,0 71.0 ± 12.9 180 ± 8,0 - Fight - Each combat consisted of 
Three 2-min rounds with 1-
min intervals 
Nelson et al.26 
 




25.5 ± 4.1 
 
 
77.9 ± 18.4,0   25.1 ± 4.0  Cycle 
Ergometric 
39.5 ± 7.0  Submaximal workload for 
30 minutes, following by 10 
minutes (80% V02 max) and 
additional 10 minutes (100% 
V0). 
Rolim et al.32 21 young 
physically active 
men 
22.3 ± 2.9 - - 25.2  ± 
2.7mg/kg² 
Treadmill - 3 minutes of warm-up at 
3km/h and 2.5% of slope. In 
sequence, increments 1km/h 











of Maximal Heart Rate, test 
was interrupted. 
 
Table 2. Description of the selected articles by author and year, time ingestion CAF, CAF dose, placebo, analysis time, HRV index, main conclusions, 
strength of evidence and effect size through Cohen’s d. 












45 minutes (~0.78mg/kg) 
100mg* 
 





(ms2), HF (nu) 
lnLF (ms2), LF 
(nu), LF/HF, HR 
During resting the CAF in 
combination with the Citrus 
Aurantium supplement induced 
increase in the sympathetic 
control without influencing the 
parasympathetic regulation. It 












0.48,  lnLF 
(ms2): 0.48,  





60 minutes (4mg/kg) 
300 ± 32 mg 
 
Capsule 
(dehydrated milk)  
6 minutes HR CAF increased HR in all tests 
performed caused by increased 










15 minutes  (~3.80mg/kg) 
300mg 
 
Capsule (starch) 1, 3, 5, 7, 10, 






SDNN, HF, LF, 
LF/HF, SAP, 
DAP, HR 
Intake of CAF delayed the 
parasympathetic recovery 








45 minutes (~5.06mg/kg) 
 400mg 




HR, DAP, SAP, 
LF/HF 
The CAF group presented 
higher HRmax during exercise. 
BP, DAP and SBP values 
remained elevated after the end 
of the exercise. The CAF 
delayed vagal reactivation after 
exercise and caused 








15 minutes (~3.80mg/kg) 
300mg 
 








parasympathetic recovery from 
exercise in individuals with 
lower cardiorespiratory 









60 minutes (5mg/kg) 







HR CAF reduced resting HR and 
there was no impact of CAF on 








60 minutes (5mg/kg) 







RMSSD, HR CAF did not delay vagal 
reactivation between 180 and 







Nelson et al.29 
 















pNN50, LF, HF, 
LF/HF, HR 
CAF in combination with 
taurine increased resting HR, 
however, no differences were 
found in the linear time domain 
and HRV frequency indices 













HR, SAP, DAP, 
SD1,SD2 
CAF accelerated 
parasympathetic reactivation in 
the submaximal exercise test in 
the first three minutes. 
High 
evidence 









300s: 0.23.  
HR = heart rate; HRmax: Heart rate peak during exercise. RMSSD = square root of the square mean of the differences between adjacent normal RR intervals; SDNN = 
standard deviation of all normal RR intervals; pNN50 = percentage of adjacent RR intervals with duration difference greater than 50ms; LF = low frequency component; 
HF = high frequency component; LF / HF = ratio between low and high frequency components; SD1: dispersion of points perpendicular to the identity line, instantaneous 
record of beat-to-beat variability; SD2: scatter of points along the identity line; long-term record of HRV; PA = systemic arterial pressure, DAP = diastolic blood pressure 
and SAP = systolic blood pressure. * They presented compounds other than CAF in the composition of the supplement offered for study participants. PLA: Placebo. 
 
SD2 at 60 
s: 0.01, 
SD2 at 
120s: 
0.0.01, 
SD2 at 
180s: 0.17, 
SD2 at 
240s: 0.06, 
SD2 at 
300s: 0.004 
 
 
